Researchers unlock clues to improving cancer treatment

patients
Credit: CC0 Public Domain

A research project led by The University of Western Australia in collaboration with Telethon Kids Institute and 13 health research organizations has identified key differences between cancers that respond to immunotherapy and those that do not.

The breakthrough, which has the potential to improve , is published in the journal Science Translational Medicine.

Immunotherapy treatment works by enhancing the body's immune response to help fight .

Scientist Dr. Rachael Zemek, who completed the work as part of her Ph.D. at UWA's National Centre for Asbestos Related Diseases and is now based at Telethon Kids Institute, said immunotherapy could result in the complete disappearance of cancer in a handful of patients, but why it worked for some people and not others was unknown.

"Through our research we found that by activating a particular immunological pathway before treatment, we could dramatically boost the response to immunotherapy treatment in mice," Dr. Zemek said.

"We developed a unique way of analyzing cancer samples before treatment and then compared the genes between responding and non-responding cancers," she said.

After analyzing the genes found within cancer samples, the researchers were surprised to see that even before immunotherapy, they could tell which cancers were going to respond.

Dr. Joost Lesterhuis, from UWA's School of Biomedical Sciences and the Telethon Kids Institute, who led the research and supervised Dr. Zemek during the study, said the team then identified drugs that could increase expression of the genes to increase the response to immunotherapy treatment.

"By preparing the before therapy, it can strengthen the response," Dr. Lesterhuis said.

"This has exciting future potential to help more cancer patients benefit from immunotherapy."

The method has not yet been tested on people with cancer who have received immunotherapy; however could begin within the next few years.


Explore further

Study pinpoints what causes relapse after cancer immunotherapy

More information: Rachael M. Zemek et al. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment, Science Translational Medicine (2019). DOI: 10.1126/scitranslmed.aav7816
Journal information: Science Translational Medicine

Citation: Researchers unlock clues to improving cancer treatment (2019, July 18) retrieved 19 October 2019 from https://medicalxpress.com/news/2019-07-clues-cancer-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
24 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more